Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets soar
Tue, 21 Oct 01:30 pm

Indian share markets remained volatile and have firmed up in the post-noon trading session. Barring oil & gas and pharma, all the sectoral indices are trading in the red with consumer durable and power stocks being the biggest gainers.

BSE-Sensex is up 128 points and NSE-Nifty is trading 37 points up. BSE Mid Cap is trading 0.8% up and BSE Small Cap index is trading up by 0.4%. The rupee is trading at 61.30 to the US dollar.

automobile stocks are trading mixed with TVS Motors and Tube Investments being the major gainers whereas Mahindra & Mahindra and Maharashtra Scooters are among major losers. As per a leading financial daily, Hero MotoCorp has outlined plans to invest in excess of Rs 50 bn that includes manufacturing plants in Columbia and Bangladesh as well as new plants being set up in Gujarat and Andhra Pradesh and a Hero Global Centre for Research and Design in Rajasthan. The company has invested Rs 10.5 bn at the Neemrana facility having 0.75 m units annual capacity. Post the setting up of this unit, the company's overall annual capacity has increased to 7.65 m units. Hero MotoCorp will commence work on the Halol plant in Gujarat in November followed by the Andhra Pradesh plant with each of them having annual capacities of 1.8 m units. Each of the Columbia and Bangladesh plants will have annual capacities of 0.15 m units. The company has targeted to set up 20 manufacturing and assembly facilities across the world to scale up its capacity to 12 m units per annum over the next five years. Hero MotoCorp stock is trading up 0.8%.

Indian Pharma stocks are trading on a mixed note today. NATCO Pharma is leading the pack of gainers, whereas Lupin and Divis Lab are trading on a weak note today. As per a leading business daily, domestic pharma companies are worried about the recent announcement of changes in Indian patent laws by the US that would increase costs for them. This will weaken their ability to provide low costs drugs. The demands of US IPR (intellectual property rights) working committee if implemented will make Indian generic drugs more costly. This is in turn will reduce India's competiveness on the low cost manufacturing front.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets soar". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.